Stoppa-Lyonnet D - Search Results

1

Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype.

Micol R, Ben Slama L, Suarez F, Le Mignot L, Beauté J, Mahlaoui N, Dubois d'Enghien C, Laugé A, Hall J, Couturier J, Vallée L, Delobel B, Rivier F, Nguyen K, Billette de Villemeur T, Stephan JL, Bordigoni P, Bertrand Y, Aladjidi N, Pedespan JM, Thomas C, Pellier I, Koenig M, Hermine O, Picard C, Moshous D, Neven B, Lanternier F, Blanche S, Tardieu M, Debré M, Fischer A, Stoppa-Lyonnet D; CEREDIH Network Investigators. Micol R, et al. J Allergy Clin Immunol. 2011 Aug;128(2):382-9.e1. doi: 10.1016/j.jaci.2011.03.052. Epub 2011 Jun 12. J Allergy Clin Immunol. 2011. PMID: 21665257

2

Inactivation of the ATM gene in T-cell prolymphocytic leukemias.

Stoppa-Lyonnet D, Soulier J, Laugé A, Dastot H, Garand R, Sigaux F, Stern MH. Stoppa-Lyonnet D, et al. Blood. 1998 May 15;91(10):3920-6. Blood. 1998. PMID: 9573030 Free article.

3

Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families.

Janin N, Andrieu N, Ossian K, Laugé A, Croquette MF, Griscelli C, Debré M, Bressac-de-Paillerets B, Aurias A, Stoppa-Lyonnet D. Janin N, et al. Br J Cancer. 1999 Jun;80(7):1042-5. doi: 10.1038/sj.bjc.6690460. Br J Cancer. 1999. PMID: 10362113 Free PMC article.

4

No evidence for germline PTEN mutations in families with breast and brain tumours.

Laugé A, Lefebvre C, Laurent-Puig P, Caux V, Gad S, Eng C, Longy M, Stoppa-Lyonnet D. Laugé A, et al. Int J Cancer. 1999 Jun 21;84(3):216-9. doi: 10.1002/(sici)1097-0215(19990621)84:3<216::aid-ijc3>3.0.co;2-e. Int J Cancer. 1999. PMID: 10371336

5

[Role of the ATM gene in genetic predisposition to cancer].

Bay JO, Uhrhammer N, Stoppa-Lyonnet D, Hall J. Bay JO, et al. Bull Cancer. 2000 Jan;87(1):29-34. Bull Cancer. 2000. PMID: 10673629 Free article. French. No abstract available.

6

No germline ATM mutation in a series of 16T-cell prolymphocytic leukemias.

Stoppa-Lyonnet D, Laugé A, Sigaux F, Stern MH. Stoppa-Lyonnet D, et al. Blood. 2000 Jul 1;96(1):374-6. Blood. 2000. PMID: 10939806 No abstract available.

7

Cancer risk in heterozygotes for ataxia-telangiectasia.

Geoffroy-Perez B, Janin N, Ossian K, Laugé A, Croquette MF, Griscelli C, Debré M, Bressac-de-Paillerets B, Aurias A, Stoppa-Lyonnet D, Andrieu N. Geoffroy-Perez B, et al. Int J Cancer. 2001 Jul 15;93(2):288-93. doi: 10.1002/ijc.1329. Int J Cancer. 2001. PMID: 11410879

8

Variation in breast cancer risk of heterozygotes for ataxia-telangiectasia according to environmental factors.

Geoffroy-Perez B, Janin N, Ossian K, Laugé A, Stoppa-Lyonnet D, Andrieu N. Geoffroy-Perez B, et al. Int J Cancer. 2002 Jun 1;99(4):619-23. doi: 10.1002/ijc.10367. Int J Cancer. 2002. PMID: 11992555

9

Phenotypic cellular characterization of an ataxia telangiectasia patient carrying a causal homozygous missense mutation.

Angèle S, Laugé A, Fernet M, Moullan N, Beauvais P, Couturier J, Stoppa-Lyonnet D, Hall J. Angèle S, et al. Hum Mutat. 2003 Feb;21(2):169-70. doi: 10.1002/humu.9107. Hum Mutat. 2003. PMID: 12552566

10

Cellular responses to ionising radiation of AT heterozygotes: differences between missense and truncating mutation carriers.

Fernet M, Moullan N, Lauge A, Stoppa-Lyonnet D, Hall J. Fernet M, et al. Br J Cancer. 2004 Feb 23;90(4):866-73. doi: 10.1038/sj.bjc.6601549. Br J Cancer. 2004. PMID: 14970866 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

492 results

Search Page

Filters